Project Grant R43AA032127
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$914K
Federal Agency
National Institute on Alcohol Abuse and Alcoholism
Awardee
Demerx, Inc. (L96RVV9Z5RJ6)
Federal Grant Program
93.273
Assistance Type
Project Grant
Place of Performance
Florida, USA
Similar Awards
This Cooperative Agreement award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), provides $999,393.00 to support Investigational New Drug (IND)-enabling studies for a novel therapeutic targeting the hypothalamic-pituitary-adrenal (HPA) axis for the treatment of Alcohol Use Disorder (AUD). The awardee, Stress Therapeutics, Inc., a for-profit company in San Diego, California, will manufacture and validate the test article,...
This $673,500 Project Grant from the National Institutes of Health's National Institute on Alcohol Abuse and Alcoholism will fund Amygdala Neurosciences, Inc. to develop new, potent, selective, and reversible inhibitors of aldehyde dehydrogenase 2 (ALDH2) for the treatment of alcohol use disorder. The goal is to implement an innovative screening technology to discover novel compounds that reduce craving and alcohol consumption by selectively inhibiting ALDH2 in a reversible manner, avoiding...
This $366,406 Project Grant was awarded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) to Yale University. The grant will be used to develop two novel human laboratory models to screen potential medications for Alcohol Use Disorder (AUD). The first model will assess a medication's ability to increase abstinence and reduce heavy drinking, which align with key FDA endpoints for AUD medication approval. The second model will...
This Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), provides $423,313 to Biosymetrics Inc. to develop an AI-driven in vivo profiling platform in zebrafish for identifying potential therapeutics for alcohol use disorder (AUD). The project aims to leverage Biosymetrics' existing AI-based zebrafish screening capabilities and experimental findings on AUD to create a commercial platform for accelerated AUD...
Under a $368,673 Project Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded on September 25, 2023, Artiam Bio Inc., a minority-owned small disadvantaged biotechnology company, is developing and evaluating second-generation partial inverse agonists targeting the type 1 cannabinoid (CB1) receptor as a potential therapy for alcohol use disorder (AUD). Artiam Bio is conducting preclinical efficacy studies of its lead CB1 receptor partial inverse agonist compound in rat...
This $223,531 Project Grant awarded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) will fund a Phase Ia/b proof-of-concept study to evaluate the use of the FDA-approved drug diclofenac as a potential novel treatment for alcohol use disorder (AUD). The study will be conducted by the University of Maryland, Baltimore and aims to determine the optimal dosage of diclofenac that increases levels of the neuroprotective metabolite...
This $499,987 Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) will fund the development of a High Throughput Alcohol Screening Platform (HT-ASP) that incorporates cortical organoids. The project aims to create an automated platform to mature, maintain, and assay over 100 organoids in culture, providing a robust and genetically diverse system for screening potential alcohol use disorder therapeutics. The...
This federal Project Grant award for $708,511 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) will fund a mechanistic trial to elucidate the effects of psilocybin on neural activity in individuals with alcohol use disorder (AUD). The study aims to evaluate the impacts of high-dose versus low-dose psilocybin on AUD patients' neural response to negative affective stimuli and alcohol cues, as well as subsequent drinking...
This federal Project Grant award of $581,869 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the CFDA 93.273 Alcohol Research Programs, will fund a human neuroscience study to investigate the role of glucocorticoid receptor (GR) antagonism in alcohol use disorder (AUD). The study will evaluate the effects of a selective GR antagonist, PT150, on behavioral, neuroendocrinological, and physiological responses to stress and alcohol in 34 participants. The research aims...
This federal Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273) federal grant program, is funding a Phase II clinical trial to evaluate the use of the drug tirzepatide (Zepbound) in adults with co-occurring alcohol use disorder and overweight/obesity. The $211,247 award supports an 8-week double-blind study at the University of Southern California to assess the effects of tirzepatide on alcohol use, weight,...